Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
Wake Forest University Health Sciences
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
Rutgers, The State University of New Jersey